DGCity
— A Window to China

China Adds 107 Medicines to Its National Reimbursement List

#Public Health Reform

China’s medical insurance administration and the human resources ministry have published the 2026 editions of two drug catalogues: the one that determines what the basic medical insurance scheme pays for, and a parallel list for commercial health insurance products.

The basic catalogue adds 107 medicines this year, 51 of which are class-1 innovative drugs, the category reserved for products with new molecular structures or genuinely novel mechanisms. That is the highest share of first-class innovations in any round of the annual adjustment so far, according to the two ministries.

The new list takes effect on January 1, 2027. Prices for the medicines that enter it are set through negotiation between the insurer and the manufacturer, a process that has become the main lever for cutting the cost of patented drugs in China since it began in 2018.

The second catalogue is the more interesting structural change. The commercial insurance innovative drug list gives private insurers a defined set of newer, more expensive products to cover, separate from the basic fund. The intent is to stop the basic scheme from being asked to pay for everything, while still giving manufacturers a route to reimbursement for therapies the public fund cannot justify.

For patients the effect is uneven and often delayed. Inclusion does not guarantee that a drug is stocked at a particular hospital, and the gap between a national list and a prescription on the ward is one of the persistent complaints about the system. Regulators have pushed hospitals to improve stocking rates in recent rounds.

For drugmakers the calculation is straightforward. Volume goes up, unit price goes down, and the question is whether the net effect covers the cost of the clinical trials that got them there. Innovative Chinese biotechs have increasingly bet on exactly this trade, pricing for the Chinese market first and exporting later.

Like(0)
未经允许不得转载:Dgcity » China Adds 107 Medicines to Its National Reimbursement List

Sign In

Forgot Password

Sign Up